Changchun High-tech (000661.SZ) subsidiary Kamaikole Lin clinical trial application has been approved.

date
11/08/2025
Zhtng cijng APP xn, Chngchn goxn (000661.SZ) fb gnggo, jnr, gngs kngg zgngsChngchn jnsi yoy yuxin zrn gngs (yxi jinchng "jnsi yoy") shudo guji yopn jind gunl j hk zhnf de yow lnchng shyn pzhn tngzhsh, jnsi yoy k mi jiolnpin de jngni shngchn yopn zhc lnchng shyn shnqng hud pzhn. Zhtng Finance APP News, Changchun High-tech (000661.SZ) announced that recently, the company's holding subsidiary - Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinsai Pharmaceutical") has received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration. The application for registration of clinical trials for domestically produced drugs of Jinsai Pharmaceutical's Kamejiao Lin Tablets has been approved.
Latest
See all latestmore